The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation
Hyperprolactinemia (HP) is one of the most common neuroendocrine disorders. In 60% of cases, pathological HP is caused by pituitary prolactin-secreting adenoma. Therapy with agonists of dopamine type 2 receptors (D2 receptor agonists) is a method of choice for the treatment of pathological HP which...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2019-09-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://omet-endojournals.ru/omet/article/viewFile/10243/7852 |